Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

Journal of Clinical Microbiology

Volumn 44, Issue 7, 2006, Pages 2612-2614

  Halvas, Elias K ^a   Aldrovandi, Grace M ^b   Balfe, Peter ^c   Beck, Ingrid A ^d   Boltz, Valerie F ^e   Coffin, John M ^e   Frenkel, Lisa M ^d   Hazelwood, J Darren ^f   Johnson, Victoria A ^f   Kearney, Mary ^e   Kovacs, Andrea ^g   Kuritzkes, Daniel R ^h   Metzner, Karin J ⁱ   Nissley, Dwight V ^j   Nowicki, Marek ^g   Palmer, Sarah ^e   Ziermann, Rainer ^k   Zhao, Richard Y ^l   Jennings, Cheryl L ^m   Bremer, James ^m   Brambilla, Don ⁿ   Mellors, John W ^a,o   more..

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j SAIC FREDERICK INC   (United States)

^k BAYER CORPORATION   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m RUSH MEDICAL COLLEGE   (United States)

ⁿ NEW ENGLAND RESEARCH INSTITUTES   (United States)

^o UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; LYSINE; RNA DIRECTED DNA POLYMERASE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS IDENTIFICATION; VIRUS MUTANT;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746191676     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00449-06     Document Type: Article

References (20)

1. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
2. Decks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
3. Delaugerre, C., M. A. Valentin, M. Mouroux, M. Bonmarchand, G. Carcelain, C. Duvivier, R. Tubiana, A. Simon, F. Bricaire, H. Agut, B. Autran, C. Katlama, and V. Calvez. 2001. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15:2189-2191.
4. Edelstein, R. E., D. A. Nickerson, V. O. Tobe, L. A. Manns-Arcuino, and L. M. Frenkel. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 36:569-572.
5. Fontaine, E., C. Riva, M. Peeters, J. C. Schmit, E. Delaporte, K. Van Laethem, K. Van Vaerenbergh, J. Snoeck, E. Van Wijngaerden, E. De Clercq, M. Van Ranst, and A. M. Vandamme. 2001. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J. Acquir. Immun. Defic. Syndr. 28:254-258.
6. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
7. Hirsch, M. S., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kurilzkes, R. T. D'Aquila, L. M. Demeter, S. M. Hammer, V. A. Johnson, C. Loveday, J. W. Mellors, D. M. Jacobsen, and D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 37:113-128.
8. Izopet, J., C. Souyris, A. Hance, K. Sandres-Saune, M. Alvarez, C. Pasquier, F. Clavel, J. Puel, and P. Massip. 2002. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis. 185:1506-1510.
9. Julias, J. G., A. L. Ferris, P. L. Boyer, and S. H. Hughes. 2002. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J. Virol. 75:6537-6546.
10. Kutyavin, I. V., I. A. Afonina, A. Mills, V. V. Gorn, E. A. Lukhlanov, E. S. Belousov, M. J. Singer, D. K. Walburger, S. G. Lokhov, A. A. Gall, R. Dempcy, M. W. Reed, R. B. Meyer, and J. Hedgpeth. 2000. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res. 28:655-661.
11. Leitner, T., E. Halapi, G. Scarlatti, P. Rossi, J. Albert, E.-M. Fenyo, and M. Uhlen. 1993. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 15:120-127.
12. Mellors, J., S. Palmer, D. Nissley, M. Kearney, E. Halvas, C. Bixby, L. Demeter, S. Eshleman, K. Bennett, S. Hart, F. Vaida, M. Wantman, J. Coffin, and S. Hammer. 2004. Low-frequency NNRTI-resistant variants contribute to failure of Efavirenz-containing regimens, abstr. 39. Abstr. 11th Conf. Retrovir. Opportunistic Infect. Foundation for Retrovirology and Human Health, San Francisco, CA.
13. Metzner, K. J., S. Bonhoeffer, M. Fischer, R. Karanicolas, K. Allers, B. Joos, R. Weber, B. Hirschel, L. G. Kostrikis, H. F. Gunthard, and the Swiss HIV Cohort Study. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188:1433-1443.
14. Nissley, D. V., E. K. Halvas, N. L. Hoppman, D. J. Garfinkel, J. W. Mellors, and J. N. Strathern. 2005. Sensitive phenotypic detection of minor drug resistant HIV-I reverse transcriptase variants. J. Clin. Microbiol. 43:5696-5704.
15. O'Meara, D., K. Wilbe, T. Leitner, B. Hejdeman, J. Albert, and J. Lundeberg. 2001. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J. Clin. Microbiol. 39:464-473.
16. Palmer, S., M. Kearney, F. Maldarelli, E. K. Halvas, C. J. Bixby, H. Bazmi, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, S. Hammer, J. W. Mellors, and J. M. Coffin. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413.
17. Palmer, S., V. Boltz, F. Maldarelli, M. Kearney E. K. Halvas, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping nonnucleoside therapy. AIDS 20:701-710.
18. Schuurman, R., D. Brambilla, T. de Groot, D. Huang, S. Land, J. Bremer, I. Benders, C. A. Boucher, and the ENVA Working Group. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18:243-248.
19. Shi, C., and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785.
20. Tsongalis, G, T. Gleeson, M. Rodina, D. Anamani, J. Ross, I. Joanisse, L. Tanimoto, and R. Ziermann. 2005. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. J. Clin. Virol. 34:268-271.